Delek US (NYSE: DK) director sells shares under 10b5-1 trading plan

Rhea-AI Filing Summary

Delek US Holdings director Zohar Shlomo sold 7,343 shares of common stock in an open-market transaction at $46.00 per share. The sale occurred on March 19, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Shlomo directly holds 6,646 Delek US shares.

Insights

Equity analyst

Pre-planned director share sale, modest in scale and routine in nature.

Director Zohar Shlomo sold 7,343 shares of Delek US Holdings common stock at $46.00 per share in an open-market transaction. Following the sale, he directly owns 6,646 shares, indicating he maintains a continuing equity stake.

The transaction was made pursuant to a Rule 10b5-1 trading plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions. Such plans are set up in advance, so the timing generally reflects pre-planned diversification or liquidity rather than a new view on the company.

There were no derivative exercises or tax-withholding events disclosed in this filing, and the derivative position table is empty. Overall, this appears to be a routine, pre-planned sale with limited informational value for assessing Delek US’s underlying business performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zohar Shlomo

(Last) (First) (Middle)

310 SEVEN SPRINGS WAY

SUITE 500

(Street)

BRENTWOOD TENNESSEE 37027

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Delek US Holdings, Inc. [ DK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		S(1)		7,343	D	$46	6,646	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Remarks:

	/s/ Misty Lavender, Attorney in Fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Delek US (DK) director Zohar Shlomo do in this Form 4?

Director Zohar Shlomo sold 7,343 shares of Delek US common stock in an open-market transaction at $46.00 per share. This SEC Form 4 records the sale and his updated direct ownership position after the trade.

How many Delek US (DK) shares did the director sell and at what price?

Zohar Shlomo sold 7,343 shares of Delek US common stock at a price of $46.00 per share. The transaction reflects a single open-market sale reported as a non-derivative transaction in the filing.

How many Delek US (DK) shares does Zohar Shlomo own after this sale?

After the reported sale, Zohar Shlomo directly holds 6,646 shares of Delek US common stock. This updated figure shows his remaining direct equity stake following the 7,343-share open-market disposition disclosed in the Form 4.

Was the Delek US (DK) share sale under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions. Such plans are pre-arranged, reducing the significance of the sale’s exact timing for investors.

Is this Delek US (DK) Form 4 a buy or sell signal from the insider?

This Form 4 reflects a sell transaction, not a purchase. Director Zohar Shlomo executed an open-market sale of 7,343 shares, but it occurred under a pre-planned Rule 10b5-1 trading plan, which typically makes the timing less indicative of a changed outlook.

Did the Delek US (DK) director exercise any options in this Form 4 filing?

No. The Form 4 shows only a non-derivative open-market sale of common stock and an empty derivative summary. There were no option exercises, conversions, or other derivative transactions reported alongside this sale in the disclosed data.